The Antibody Drug Conjugate Summit 2017 covers topics such as:
Ensure product and process robustness Make more evidence-based decisions
Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action
Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology Learn about advances in Protein Modeling and Engineering Breakthroughs
Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity
The Antibody Drug Conjugate Summit 2017 brings together senior attendees from:
Research & Development
Discovery Chemistry
Toxicology
Antibody Discovery
Protein Engineering
Biologics
Biotherapeutics
Molecular Biology
Process Sciences
Oncology Molecules
Development Analytics and New Technologies
Biopharmaceutical Development
Biologics Discovery and Design
Clinical Assay
As well as:
Chief Development Officers
Chief Technology Officers
Senior Research Officers
Chief Scientific Officers
Past Events
Antibody Drug Conjugate Summit 2017 - 22-23 May 2017, Novotel Lisboa, Lisbon, Portugal (66831)
Important
Please, check "Antibody Drug Conjugate Summit" official website for possible changes, before making any traveling arrangements
We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept", you consent to our use of cookies. You can manage your preferences or learn more by clicking "Customize" or visiting our Cookies Policy page.